在地幔细胞淋巴瘤的量身定制方法:通过专家小组的意见来完善治疗范式
Won Seog Kim1,2, Mubarak Al Mansour3,4, Chan Cheah5,6
1Department of Internal Medicine, Division of Hematology Oncology, Samsung Medical Center, Seoul, South Korea.
Leukemia & lymphoma
|March 17, 2026
概括
膜细胞淋巴瘤 (MCL) 治疗正在随着新疗法,如布鲁顿的氨酸激酶抑制剂 (BTKi) 的发展而发展. 专家们讨论了个性化的方法和干细胞移植对MCL患者的变化作用.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 膜细胞淋巴瘤 (MCL) 是一种具有挑战性的临床管理的侵袭性非霍奇金B细胞淋巴瘤.
- 最近的治疗进展正在改变MCL治疗模式.
研究的目的:
- 探索自主干细胞移植 (ASCT) 在MCL中不断变化的作用.
- 讨论ASCT不合格患者的治疗策略.
- 突出个性化治疗方法以优化结果.
主要方法:
- 专家意见文章基于14名国际专家的见解.
- 审查新兴疗法,包括布鲁顿的氨酸激酶抑制剂 (BTKi),CAR-T疗法和无化疗方案.
- 讨论个性化治疗因素:遗传标记,并发症和医疗保健资源.
主要成果:
- BTKi正在成为ASCT不合格患者的有效一线选择.
- 在MCL管理中,BTKi是ASCT的强大替代品.
- 个性化治疗策略对于优化MCL的临床结果至关重要.
结论:
- 医疗环境正在转向个性化护理.
- 新兴疗法提供了新的希望,但它们的好处和局限性需要仔细考虑.
- 全球合作对于推动MCL治疗和患者护理至关重要.
更多相关视频
相关概念视频
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K


